Tue.Feb 20, 2024

article thumbnail

Daiichi Sankyo plots €1B expansion to beef up antibody-drug conjugate production in Germany

Fierce Pharma

After laying out plans to absorb a pair of production subsidiaries in October, Japan’s Daiichi Sankyo is doubling down on its quest to dominate the red-hot antibody-drug conjugate (ADC) field. | Aiming to beef up development and manufacturing of antibody-drug conjugates, Daiichi Sankyo is plugging roughly €1 billion ($1.08 billion) into an expansion of its production facility in Pfaffenhofen an der Ilm, Germany.

article thumbnail

Enhancing Patient Care: 4 Strategies for Life Sciences Companies

Salesforce

For many people, a sudden tingling in the leg or a feeling of numbness in the arm isn’t too much cause for alarm. The tingling or the numbness goes away after a little while, and they go on with their lives. But for Brooke Eby, an abrupt limp on her way to a conference one day ultimately led to a diagnosis of amyotrophic lateral sclerosis (ALS) at the age of 33.

Patients 137
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Touting commercial and R&D progress, AstraZeneca hikes CEO Pascal Soriot's pay to nearly £17M

Fierce Pharma

AstraZeneca, having surpassed its long-term $45 billion revenue goal last year, has handsomely rewarded its chief executive. | AstraZeneca CEO Pascal Soriot’s compensation package makes him the current top contender for 2023’s highest-paid pharma CEO in Europe. Still, as in years past, not everyone is pleased with Soriot’s 2023 windfall.

Pharma 299
article thumbnail

Tools for Better Data Interoperability Are Here — But Providers Aren’t Adopting Them

MedCity News

There are plenty tools and data sharing standards available to foster a more cohesive and integrated approach to healthcare interoperability. However, providers aren’t really adopting these tools, experts said during a recent panel.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Another tough decision for Bayer as it plans to slash dividend by 95% to reduce debt

Fierce Pharma

Since he took over as CEO at Bayer nine months ago, Bill Anderson had had to make tough decisions to try to get the floundering conglomerate back on track. | Bayer plans to cut its investor dividends to help reduce the company’s debt. Over three years, Bayer intends to pay out the legal minimum. For 2023, that comes to €0.11 per share compared to the €2.40 the company paid out per share in 2022.

286
286
article thumbnail

Curing MedTech’s Cybersecurity Contagion

MedCity News

There is growing and coordinated momentum behind the goal of ensuring connected medical devices improve people’s lives without introducing them to cybersecurity threats and associated safety risks. There also is a proven playbook for implementing the type of multi-layered, security-by-design strategies these initiatives advocate.

Safety 122

More Trending

article thumbnail

Sanofi, Denali Neuro Drug Fails Mid-Stage Trial in ALS; MS Study Is Continuing

MedCity News

Sanofi, which is leading development of the Denali Therapeutics-partnered molecule, disclosed little about the clinical trial results in ALS. But this Phase 2 failure follows the 2020 clinical trial pause of a different partnered molecule that addresses the same target.

Leads 119
article thumbnail

GSK’s long-acting HIV med Cabenuva beats daily therapy in patients who've faced adherence hurdles

Fierce Pharma

GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. | GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. Now, the injection has beaten daily drugs in individuals who’ve faced issues adhering to their medications.

Patients 246
article thumbnail

Zocdoc Launches Tool To Help Connect Patients to the Right Providers

MedCity News

About 57% of patients have gone to a doctor’s appointment to discover that the provider was not the right one for their condition, according to new research from Zocdoc. Because of this, the company launched a new tool called Guided Search that helps pair patients with the correct provider.

Patients 119
article thumbnail

A Person-Centered Approach to Achieving Long-Term Success

Fierce Pharma

This week on “The Top Line,” we’re speaking with Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences about how advancements in HIV treatment research have enabled indiv | This week, we’re speaking with Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences about how advancements in HIV treatment research have enabled individuals to lead longer and healthier lives by taking and staying on medication.

Leads 227
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

FDA starts review of Argenx drug in rare disease CIDP

pharmaphorum

The FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in rare autoimmune disease chronic inflammatory demyelinating polyneuropathy (CIDP).

FDA 116
article thumbnail

AstraZeneca touts 'overwhelming' Tagrisso win among 3 lung cancer portfolio advancements

Fierce Pharma

AstraZeneca is celebrating a trio of recent advancements for its portfolio in non-small cell lung cancer (NSCLC). | AstraZeneca is celebrating a trio of advancements for its portfolio in non-small cell lung cancer, including an “overwhelming efficacy benefit” for Tagrisso in early-stage disease. Besides the trial result, AZ touted an FDA approval for Tagrisso's chemo combo in metastatic tumors, plus an application acceptance for a Daiichi Sankyo-partnered TROP2 antibody-drug conjugate in a

FDA 162
article thumbnail

Pfizer’s ulcerative colitis drug Velsipity gets EU okay

pharmaphorum

The European Commission has approved Pfizer’s S1P receptor modulator Velsipity as a treatment for ulcerative colitis (UC), raising the pressure on Bristol-Myers Squibb’s first-to-market Zeposia.

Marketing 115
article thumbnail

Fabrazyme litigation back in play for Sanofi's Genzyme as appeals court overturns dismissal of 2020 lawsuit

Fierce Pharma

It’s been 15 years since Genzyme began rationing the Fabry disease treatment Fabrazyme after a shortage caused by contamination at a manufacturing site, marking the start of many years of litigatio | Sanofi's Genzyme was accused of causing injuries after contaminated doses of its Fabry disease drug led to a shortage, during which the company rationed the drug.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Bayer takes novel deep vein thrombosis drug into phase 2

pharmaphorum

Bayer takes anti-alpha2 antiplasmin antibody BAY3018250 into phase 2 as a deep vein thrombosis treatment, hoping to improve on thrombolytics.

115
115
article thumbnail

Patient Death Prompts FDA Hold on Tests of Drug in Atopic Dermatitis & Asthma

MedCity News

The FDA clinical hold follows a patient death from liver failure that may be associated with zelnecirnon, an experimental Rapt Therapeutics drug. The biotech notes that no other patient has experienced liver problems and this safety signal has not been seen in any other tests of the molecule.

FDA 115
article thumbnail

Bioptimus is born with $35m for foundation model for biology

pharmaphorum

Google DeepMind and Owkin scientists have joined forces to create Bioptimus, an AI startup that aims to develop a foundation model for biology

115
115
article thumbnail

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge? [Sponsored]

MedCity News

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Value and potential of IoT and AI for chronic diseases treatment

PharmaVoice

A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

Marketing 104
article thumbnail

Is Europe About to Overtake the U.S.’s Leadership Position in Healthcare Sustainability via Reprocessing?

MedCity News

FDA’s regulation of single-use device reprocessing effectively made the U.S. the leader in EP sustainability efforts early on. However, very little has been done to build on this early leadership.

article thumbnail

AbbVie looks internally for its new CEO, naming COO Michael

pharmaphorum

AbbVie reveals its CEO succession plan, as COO Robert Michael prepares to take over from Richard Gonzalez on July 1

103
103
article thumbnail

Register for MedCity INVEST in Chicago Where Investors and Healthcare Startups Connect

MedCity News

The conference, scheduled for May 21-22 at the Ritz Carlton in Chicago, is the premier boutique healthcare investment event in the U.S.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

FDA Accepts Biologics License Application for Datopotamab Deruxtecan

Pharmaceutical Commerce

The agency will make its final decision surrounding the locally advanced or metastatic nonsquamous NSCLC drug —based on results from the TROPION-Lung01 Phase III trial—by Q4 2024.

FDA 101
article thumbnail

Researchers develop nanogel to deliver anti-inflammatory drugs for spinal cord injury

PharmaTimes

The nanogels, in combination with rolipram, contributed to the recovery of injured tissue

98
article thumbnail

Single-use technology propelling upstream bioprocessing market expansion

European Pharmaceutical Review

A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78 million by 2029. Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85 percent between 2022 and 2029. The rising productivity of cell lines has improved the performance of upstream processing with low cost and high process reproducibility, the report explained.

article thumbnail

Xolair amplifies reach after FDA approval for treating food allergies 

Pharmaceutical Technology

Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.

Food 94
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

New initiative to improve patient retention in paediatric clinical trials

PharmaTimes

The new programme will engage with children and young people under the age of 18 years

article thumbnail

Kite’s next-gen CAR-T aims include quicker production and more disease targets

PharmaVoice

While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

article thumbnail

What Is A Diabetes Sales Specialist? With O’Neal Ford

Evolve Your Success

In the dynamic realm of medical device sales, the possibilities are limitless. Dive into the role of a Diabetes Sales Specialist and explore the diverse opportunities that await. In this episode for Black History Month, Samuel Adeyinka interviews District Sales Trainer & Diabetes Sales Specialist, O’Neal Ford , to shed light on his role. Discover the importance of curiosity and adaptability in the field as O’Neal discusses the evolving landscape of endocrinology and the impact of

Sales 59
article thumbnail

Ultimovacs bags EMA orphan drug status for cancer vaccine

Pharmaceutical Technology

Following FDA orphan designation in 2023, the company is eligible for market exclusivity in mesothelioma for both regions.

FDA 59
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A